Answers are grounded in this paper and cite their sources.
This evaluation proposes behavioural robustness to predict disease risk in clinical datasets, suggesting new assessment methods for interventions.
The dominant paradigm in machine learning-based disease risk prediction assesses models exclusively through cross-sectional accuracy metrics, leaving unanswered whether temporal model predictions respond to simulated lifestyle intervention in a physiologically plausible manner. This paper proposes behaviouralrobustness(BR) as a new evaluation criterion fortemporal disease risk models, complementing accuracy by quantifying trajectory-level plausibility under controlled intervention. Our core contribution is the BR metric itself—not a novel model architecture. We instantiate BR using a hybrid LSTM–Transformer framework and evaluate it across two synthetic cohorts used as controlled metric-validation conditions (Pima, N=768; NHANEScalibrated, N=2,000) and two real clinical datasets where BR is computed on actual patient trajectories (UCI Diabetes CGM,N=70; Diabetes 130-US Hospitals EHR, N=5,246). Against five published baselines, the non-personalised Transformer achieves the highest AUC on UCI (0.897) and NHANES (0.695). Statistically significant behavioural inertia is observed on all four datasets (Wilcoxon p<10−8); BR is consistently low (0.003–0.022), within the range implied by published intervention trial effect sizes. We make no claim that synthetic BR values substitute for real-world evidence; the real-data results on Diabetes-130 (N=5,246, p=1.71×10−284) constitute the primary empirical contribution. External validation on MIMIC-III and UK Biobank is identified as the essential next step
No takes yet. Share an insight, caveat, or question.
nanda et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: